BioXconomy is part of the Informa Connect Division of Informa PLC
Informa PLC
|
ABOUT US
|
INVESTOR RELATIONS
|
TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
About
Events
Advertise
Stay Updated
Stay Updated
Investment
Related Topics
VC/PE
Seed Funding
IPOs
Recent in
Investment
See All
dollar bills
Investment
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
by
Millie Nelson
Jan 15, 2025
2 Min Read
JPM written on wooden blocks in blue
Investment
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
by
Millie Nelson
Jan 14, 2025
2 Min Read
Innovation
Related Topics
Hubs
Academic Research
R&D Technology
Recent in
Innovation
See All
Image of China banknotes with a magnifying glass indicating dealmaking in Asia
Hubs
Eyes on Asia: BIOSECURE, Merck & Hansoh, Roche adds ADC, and Samsung
Eyes on Asia: BIOSECURE, Merck & Hansoh, Roche adds ADC, and Samsung
by
Dan Stanton
Jan 8, 2025
5 Min Read
UK FLAG
Innovation
Charles River launches UK incubator program
Charles River launches UK incubator program
by
Millie Nelson
Dec 28, 2024
2 Min Read
Partnering
Related Topics
Licensing
M&A
Deals
Best Practices
Recent in
Partnering
See All
Novo Nordisk logo on a window
Business Strategy
Novo on the ‘ins and outs’ of its nucleic acid growth
Novo on the ‘ins and outs’ of its nucleic acid growth
by
Dan Stanton
Jan 16, 2025
5 Min Read
dollar bills
Investment
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
by
Millie Nelson
Jan 15, 2025
2 Min Read
Business Strategy
Related Topics
Scaling/Commercialization
Growth Strategy
ESG
Outsourcing
Legal
Recent in
Business Strategy
See All
Novo Nordisk logo on a window
Business Strategy
Novo on the ‘ins and outs’ of its nucleic acid growth
Novo on the ‘ins and outs’ of its nucleic acid growth
by
Dan Stanton
Jan 16, 2025
5 Min Read
dollar bills
Investment
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
by
Millie Nelson
Jan 15, 2025
2 Min Read
Home
Oncology
Oncology
JPM written on wooden blocks in blue
Investment
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
by
Millie Nelson
Jan 14, 2025
2 Min Read
Reverse arrow
Partnering
Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange
Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange
by
Richard Daverman
Oct 31, 2024
3 Min Read
BIO-EUROPE COVERAGE
Novo Nordisk sign
Business Strategy
Lessons and blessings: The Novo Nordisk way
Lessons and blessings: The Novo Nordisk way
Michael May, PhD, President, CCRM discusses Canada as a place for life sciences in this video.
Hubs
Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move
Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move
Shaking hands
Partnering
Picky pharma prone to better proven partners amid dealmaking downturn
Picky pharma prone to better proven partners amid dealmaking downturn
Hervé Ansanay, Biotech Alliance Manager, discusses the features of the RESEAU SATT - SATT NETWORK
Hubs
RESEAU SATT, the Best of French Deep Tech
RESEAU SATT, the Best of French Deep Tech
photo of Golden Gate Bridge over the bay
Jan 13 - Jan 15, 2025
Jan 13 - Jan 15, 2025
An all-inclusive healthcare conference at Hilton Union Square, San Francisco
Register
Latest
Novo Nordisk logo on a window
Business Strategy
Novo on the ‘ins and outs’ of its nucleic acid growth
Novo on the ‘ins and outs’ of its nucleic acid growth
dollar bills
Investment
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM written on wooden blocks in blue
Investment
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.
Stay Updated